These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

63 related articles for article (PubMed ID: 12113078)

  • 1. GlycoDesign expands phase II clinical trials for GD0039.
    Expert Rev Anticancer Ther; 2001 Dec; 1(4):507-8. PubMed ID: 12113078
    [No Abstract]   [Full Text] [Related]  

  • 2. Signal-transduction inhibitors in renal cell carcinoma.
    Vogelzang NJ; Sternberg CN
    BJU Int; 2007 May; 99(5 Pt B):1289-95. PubMed ID: 17441926
    [No Abstract]   [Full Text] [Related]  

  • 3. Technology evaluation: TroVax, Oxford BioMedica.
    Reinis M
    Curr Opin Mol Ther; 2004 Aug; 6(4):436-42. PubMed ID: 15468602
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Systemic therapy for recurrent endometrial cancer: a review of North American trials.
    Dellinger TH; Monk BJ
    Expert Rev Anticancer Ther; 2009 Jul; 9(7):905-16. PubMed ID: 19589030
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II trials in journal of clinical oncology.
    Cannistra SA
    J Clin Oncol; 2009 Jul; 27(19):3073-6. PubMed ID: 19451415
    [No Abstract]   [Full Text] [Related]  

  • 6. Predicting success in phase III studies from phase II results: a new paradigm is needed.
    Leff R; Andrews M
    J Clin Oncol; 2008 Jul; 26(21):3653-4; author reply 3654-5. PubMed ID: 18640948
    [No Abstract]   [Full Text] [Related]  

  • 7. Stat bite: Treatment trials in the PDQ clinical trials database, by phase.
    J Natl Cancer Inst; 2004 Sep; 96(18):1355. PubMed ID: 15367566
    [No Abstract]   [Full Text] [Related]  

  • 8. Examining heterogeneity in phase II trial designs may improve success in phase III.
    Tuma RS
    J Natl Cancer Inst; 2008 Feb; 100(3):164-6. PubMed ID: 18230788
    [No Abstract]   [Full Text] [Related]  

  • 9. Review of phase II trial designs used in studies of molecular targeted agents: outcomes and predictors of success in phase III.
    El-Maraghi RH; Eisenhauer EA
    J Clin Oncol; 2008 Mar; 26(8):1346-54. PubMed ID: 18285606
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II oncology trials: let's be positive.
    Ratain MJ
    Clin Cancer Res; 2005 Aug; 11(16):5661-2. PubMed ID: 16115898
    [No Abstract]   [Full Text] [Related]  

  • 11. [Clinical results of Nexavar for the treatment of kidney cancer].
    Escudier B
    Prog Urol; 2007 Feb; 17(1 Suppl 1):150-3. PubMed ID: 17571640
    [No Abstract]   [Full Text] [Related]  

  • 12. Clinical trials of novel and targeted therapies: endpoints, trial design, and analysis.
    Suman VJ; Dueck A; Sargent DJ
    Cancer Invest; 2008 Jun; 26(5):439-44. PubMed ID: 18568764
    [No Abstract]   [Full Text] [Related]  

  • 13. Temsirolimus in renal cell carcinoma.
    Otto T; Eimer C; Gerullis H
    Transplant Proc; 2008 Dec; 40(10 Suppl):S36-9. PubMed ID: 19100905
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SNS-595, a naphthyridine cell cycle inhibitor and stimulator of apoptosis for the treatment of cancers.
    Mills DA; Fekrazad HM; Verschraegen CF
    Curr Opin Investig Drugs; 2008 Jun; 9(6):647-57. PubMed ID: 18516764
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Commentary on "European collaboration in trials of new agents for children with cancer" by Ablett et al.
    Smith MA; Anderson BD
    Eur J Cancer; 2004 Aug; 40(12):1893-5. PubMed ID: 15288292
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II trial of bisantrene for advanced hypernephroma.
    Scher H; Schwartz S; Yagoda A; Watson R; Faye L
    Cancer Treat Rep; 1982 Aug; 66(8):1653-5. PubMed ID: 7105056
    [No Abstract]   [Full Text] [Related]  

  • 17. Improving the design of phase II trials of cytostatic anticancer agents.
    Stone A; Wheeler C; Barge A
    Contemp Clin Trials; 2007 Feb; 28(2):138-45. PubMed ID: 16843736
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drug evaluation: MGCD-0103, a histone deacetylase inhibitor for the treatment of cancer.
    Kell J
    Curr Opin Investig Drugs; 2007 Jun; 8(6):485-92. PubMed ID: 17621879
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Objective responses in patients with malignant melanoma or renal cell cancer in early clinical studies do not predict regulatory approval.
    Goffin J; Baral S; Tu D; Nomikos D; Seymour L
    Clin Cancer Res; 2005 Aug; 11(16):5928-34. PubMed ID: 16115935
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Toxicity associated with the long-term use of targeted therapies in patients with advanced renal cell carcinoma.
    Shepard DR; Garcia JA
    Expert Rev Anticancer Ther; 2009 Jun; 9(6):795-805. PubMed ID: 19496716
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.